Skip to main content
Levi Garraway, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

LeviAGarrawayMD

Oncology • Boston, MA

Associate Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Are you Dr. Garraway?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 89 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Levi Garraway, MD is an oncologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts. He is affiliated with Dana-Farber Cancer Institute and is an Associate Professor at Harvard Medical School.

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2005
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2001
  • Harvard Medical School
    Harvard Medical SchoolClass of 1999

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2001 - 2018

Awards, Honors, & Recognition

  • Elected Member The American Society for Clinical Investigation, 2009

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People with Relapsing Forms of Multiple Sclerosis
    Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People with Relapsing Forms of Multiple SclerosisMay 17th, 2023
  • FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
    FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)May 5th, 2023
  • Roche Blood Cancer Drug Columvi Gets EMA Panel Recommendation for EU Approval
    Roche Blood Cancer Drug Columvi Gets EMA Panel Recommendation for EU ApprovalApril 28th, 2023
  • Join now to see all

Grant Support

  • The Use Of Whole-Exome Sequencing To Guide The Care Of Cancer PatientsNational Human Genome Research Institute2012
  • High-Throughput Tumor Genomic Profiling By Massively Parallel SequencingNational Cancer Institute2011
  • High-Throughput Oncogene Mutation Detection In Human CancerNational Cancer Institute2010–2011
  • Integrated Functional Genomic Analyses Of MelanomaNational Cancer Institute2005–2009
  • Functional Analysis Of The PTEN Tumor Suppressor ProteinNational Cancer Institute2005–2009
  • High-Throughput Oncogene Mutation Detection In Human CancerNational Cancer Institute2007–2008
  • Defining Melanoma Therapeutic Avenues By Integrative Functional GenomicsOffice Of The Director, National Institutes Of Health2007
  • Molecular Genetics Of Parasite VirulenceNational Human Genome Research Institute1992–1998

Professional Memberships

Hospital Affiliations

Dr. Levi Garraway, Dr. Levi Garraway, MD, Dr. L Garraway, Dr. Levi A Garraway